$78.58
3.34% yesterday
Nasdaq, Nov 25, 10:13 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$78.58
-46.59 37.22% 1M
-61.71 43.99% 6M
-0.35 0.44% YTD
+8.28 11.78% 1Y
+55.48 240.17% 3Y
+59.85 319.54% 5Y
+62.58 391.13% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+2.54 3.34%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Market capitalization $2.64b
Enterprise Value $2.83b
P/E (TTM) P/E ratio 84.19
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.04
P/S ratio (TTM) P/S ratio 6.58
P/B ratio (TTM) P/B ratio 12.56
Revenue growth (TTM) Revenue growth 109.09%
Revenue (TTM) Revenue $401.09m
EBIT (operating result TTM) EBIT $31.46m
Free Cash Flow (TTM) Free Cash Flow $-120.51m
Cash position $330.09m
EPS (TTM) EPS $0.93
P/E forward 81.61
P/S forward 6.10
EV/Sales forward 6.53
Short interest 30.54%
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
80%
Hold
20%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
401 401
109% 109%
100%
- Direct Costs 163 163
152% 152%
41%
238 238
87% 87%
59%
- Selling and Administrative Expenses 138 138
38% 38%
34%
- Research and Development Expense 50 50
62% 62%
13%
49 49
1,214% 1,214%
12%
- Depreciation and Amortization 18 18
176% 176%
4%
EBIT (Operating Income) EBIT 31 31
389% 389%
8%
Net Profit 33 33
191% 191%
8%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Negative
The Motley Fool
about 4 hours ago
In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Positive
The Motley Fool
3 days ago
2 Hypergrowth Stocks That Are Screaming Buys in November
Neutral
PRNewsWire
7 days ago
ANDOVER, Mass. , Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the ...
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 584
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today